Daygnosys
About
Dyagnosys is a B2B SaaS company revolutionizing workplace mental health through AI-powered, privacy-first wellbeing assessment technology. Our platform combines clinically-validated psychometric tools (GAD-7) with real-time biometric analysis to provide organizations with unprecedented visibility into employee wellbeing—without compromising privacy.
Our Mission: To make mental health monitoring as accessible and routine as physical health monitoring, enabling early intervention and preventing burnout before it impacts performance.
The Problem: 76% of workers report burnout symptoms, costing the global economy $1 trillion annually in lost productivity due to depression and anxiety. Current solutions fail because they store sensitive biometric data in the cloud, rely on infrequent self-reported surveys, and lack clinical validation.
Our Solution: Dyagnosys is the first wellbeing assessment platform combining clinical validation (GAD-7 anxiety screening), biometric intelligence (18 behavioral signals via camera and voice), privacy-first architecture (hybrid on-device processing), and enterprise compliance (GDPR, LGPD, HIPAA-ready). All biometric data is processed on-device using MediaPipe and WebLLM—raw data never leaves the user's device.
Traction: Product launched with full biometric capabilities, first enterprise pilot secured with Petrobras, active clinical trial through Brazil-Switzerland bilateral agreement, and partnerships with ApexBrasil, Sebrae DF, and UFMG. Headquartered in Spain with operations across EU and LATAM.
Team: Founded by experienced leaders in enterprise SaaS, AI/ML engineering, clinical psychology, and B2B sales, with an advisory board including experts from WHO, technical universities, and Fortune 500 companies.
Market Target
Main Sector of Activity (SINGLE CHOICE)
Field of aplication (Multiple choice)
Representatives
CEO
Daygnosys